Expression and function of anti-inflammatory interleukins: The other side of the vascular response to injury

Current Vascular Pharmacology

Volumn 7, Issue 3, 2009, Pages 267-276

  Cuneo, Anthony A ^a   Autieri, Michael V ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Endothelial cell; Inflammation; Interleukin; NF B; Restenosis; Smooth muscle cell

Indexed keywords

CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 4; MESSENGER RNA; RECOMBINANT INTERLEUKIN 10; TRANSCRIPTION FACTOR; ANTIINFLAMMATORY AGENT; AUTACOID; INTERLEUKIN DERIVATIVE;

ARTERY INTIMA PROLIFERATION; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; AUTOCRINE EFFECT; AUTOREGULATION; BLOOD VESSEL INJURY; BLOOD VESSEL REACTIVITY; CORONARY ARTERY DISEASE; CYTOKINE RELEASE; DISEASE COURSE; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; GENE EXPRESSION REGULATION; HUMAN; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; INFLAMMATION; MORTALITY; NONHUMAN; PARACRINE SIGNALING; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; REVIEW; RNA STABILITY; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TH1 CELL; TH2 CELL; TRANSCRIPTION REGULATION; TRANSLUMINAL CORONARY ANGIOPLASTY; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE; VASCULITIS; BIOLOGICAL MODEL; IMMUNOLOGY; PHYSIOLOGY;

ANTI-INFLAMMATORY AGENTS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKINS; MODELS, IMMUNOLOGICAL; MUSCLE, SMOOTH, VASCULAR; SIGNAL TRANSDUCTION; VASCULAR DISEASES;

EID: 69149085564     PISSN: 15701611     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016109788340721     Document Type: Review

References (111)

1. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-74.
2. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med 1999; 340: 115-26.
3. Welt FGP, Rogers C. Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 2002; 22: 1769-76.
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature1993; 362: 801-9.
5. Ventura HO, Mehra MR, Smart, FW. Cardiac allograft vasculopathy: Current concepts. Am Heart J 1995; 129: 791-8.
6. Libby P, Salomon R, Payne D, Schoen F, Pober J. Functions of vascular wall cells related to development of Transplantation-associated coronary arteriosclerosis. Transplant Proc 1989; 6: 3677-84.
7. Barnhart G, Pascoe E, Mills S. Accelerated coronary arteriosclerosis in cardiac transplant recipients. Transplant Rev 1987; 1: 31-46.
8. IP J, Fuster V, Badimon L, Badimon J, Taubman M, Chesebro J. Syndromes of Accelerated Atherosclerosis: Role of vascular injury and smooth muscle cell proliferation. J Am Coll Cardiol 1990; 15: 1667-87.
9. Schwartz R, Murphy J, Edwards W, Camrud A, Vlietstra R, Holmes D. Restenosis after balloon angioplasty: a practical proliferative model in porcine coronary arteries. Circulation 1990; 82: 2190-200.
10. Raines E, Ferri N. Cytokines affecting endothelial and smooth muscle cells in vascular disease. J Lipid Res 2005; 46: 1081-92.
11. Singer C, Sonemany S, Baker K, Gerthoffer W. Synthesis of immune modulators by smooth muscles. BioEssays 2004; 26: 646-55.
12. Von der Thüsen J, Kuiper J, van Berkel T, Biessen E. Interleukins in atherosclerosis: molecular pathways and therapeutic potential. Pharmacol Rev 2003; 55: 133-66.
13. Kleemann R, Zadelaar S, Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008; 79: 360-76.
14. Paul W. Interleukin 4: a protypic immunoregulatory lymphokine. Blood 1991; 77: 1859-70.
15. Godfraind C, Louahed J, Faulkner H, Vink A, Warnier G, Grencis R, et al. Intraepithelial infiltration by mast cells with both connective tissue-type and mucosal-type characteristics in gut, trachea, and kidneys of IL-9 transgenic mice. J Immunol 1998; 160: 3989-96.
16. Gounni A, Hamid Q, Rahman S, Hoeck J, Yang J, Shan L. IL-9-mediated induction of eotaxin1/CCL11 in human airway smooth muscle cells. J Immunol 2004; 173: 2771-9.
17. De Waal Malefyt R, Yssel H, Roncarolo M, Spits H, de Vries J. Interleukin-10. Curr Opin Immunol 1992; 4: 314-20.
18. Von Der Thusen J, Kuiper J, Fekkes M, De Vos P, Van Berkel T, Biessen E. Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr-/- mice. FASEB J 2001; 15: 2730-2.
19. Schwertschlag U, Trepicchio W, Dykstra K, Keith J, Turner K, Dorner A. Hematopoietic, immunomodulatory and epithelial effects of interleukin-11. Leukemia 1999; 13: 1307-15.
20. Trepicchio W, Dorner A. Interleukin-11. A gp130 cytokine. Ann NY Acad Sci 1998; 29: 12-21.
21. Trepicchio W, Bozza M, Pedneault G, Dorner A. Recombinant human IL-11 attenuates the inflammatory response through down-regulation of proinflammatory cytokine release and nitric oxide production. J Immunol 1996; 157: 3627-34.
22. Zurawski G, de Vries J. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 1994; 15: 19-26.
23. De Waal Malefyt R, Figdor C, Huijbens R, Mohan-Peterson S, Bennett B, Culpepper J, et al. Effects of IL-13 on phenotype, cytokine production, and cytotoxic function of human monocytes. Comparison with IL-4 and modulation by IFN-gamma or IL-10. J Immunol 1993; 151: 6370-81.
24. Gallagher G, Dickensheets H, Eskdale J, Izotova L, Mirochnitchenko O, Peat J, et al. Cloning, expression and initial characterization of interleukin-19 (IL-19), a novel homologue of human interleukin-10 (IL-10). Genes Immun 2000; 1: 442-50.
25. Gallagher G, Eskdale E, Jordan W, Peat J, Campbell J, Boniotto M, et al. Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses. Int Immunopharmacol 2004; 4: 615-26.
26. Jordan W, Eskdale J, Boniotto M, Lennon G, Peat J, Campbell JDM, et al. Human IL-19 regulates immunity through autoinduction of IL-19 and production of IL-10. Eur J Immunol 2005; 35: 1576-82.
27. Sa S, Valdez P, Wu J, Jung K, Zhong F, Hall L, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007; 178: 2229-40. 28 Tedgui A, Mallat Z. Anti-Inflammatory mechanisms in the vascular wall. Circulation Res 2001; 88; 877-87.
28. Paukku K, Silvennoinen O. STATs as critical mediators of signal transduction and transcription: lessons learned from STAT5. Cytokine Growth Factor Rev 2004; 15: 435-55.
29. Darnell J Jr. STATs and gene regulation. Science 1997; 277: 1630-5.
30. Murray P. STAT3-mediated anti-inflammatory signalling. Biochem Soc Trans 2006; 34: 1028-31.
31. Qing M, Nimmesgern A, Heinrich P, Schumacher K, Vazquez-Jimenez J, Hess J, et al. Intrahepatic synthesis of tumor necrosis factor-alpha related to cardiac surgery is inhibited by interleukin-10 via the Janus kinase (Jak)/signal transducers and activator of transcription (STAT) pathway. Crit Care Med 2003; 31: 2769-75.
32. Hamilton T, Ohmori Y, Tebo J, Kishore R. Regulation of macrophage gene expression by pro- and anti-inflammatory cytokines. Pathobiology 1999; 67: 241-4.
33. Lejeune D, Demoulin J, Renauld J. Interleukin 9 induces expression of three cytokine signal inhibitors: cytokine-inducible SH2-containing protein, suppressor of cytokine signalling (SOCS)-2 and SOCS-3, but only SOCS-3 overexpression suppresses interleukin 9 signalling. Biochem J 2001; 353(Pt 1): 109-16.
34. Albanesi C, Fairchild H, Madonna S, Scarponi C, De Pità O, Leung D, et al. IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3. J Immunol 2007; 179: 984-92.
35. Tenney R, Stansfield K, Pekala P. Interleukin 11 signaling in 3T3-L1 adipocytes. J Cell Physiol 2005; 202: 160-6.
36. Parrish-Novak J, Xu W, Brender T, Yao L, Jones C, West J, et al. Interleukins 19, 20, and 24 signal through two distinct receptor complexes. Differences in receptor-ligand interactions mediate unique biological function. J Biol Chem 2002; 277: 47517-23.
37. Tian Y, Sommerville L, Cuneo A, Kelemen S, Autieri M. Expression and suppressive effects of interleukin-19 on vascular smooth muscle cell pathophysiology and development of intimal hyperplasia. Am J Pathol 2008; 173: 901-9.
38. Cooney R. Suppressors of Cytokine Signaling (SOCS): Inhibitors of the JAK/STAT Pathway. Shock 2002; 17: 83-90.
39. Davey H, McLachlan M, Wilkins R, Hilton D, Adams T. STAT5b mediates the GH-induced expression of SOCS-2 and SOCS-3 mRNA in the liver. Mol Cell Endocrinol 1999; 158: 111-6.
40. Chen X, Losman J, Rothman P. SOCS proteins, regulators of intracellular signaling. Immunity 2000; 13: 287-90.
41. Fujimoto M, Naka T. Regulation of cytokine signaling by SOCS family molecules. Trends Immunol 2003; 24: 659-66.
42. Ding Y, Chen D, Tarcsafalvi A, Su R, Qin L, Bromberg J. Suppressor of cytokine signaling 1 inhibits IL-10-mediated immune responses. J Immunol 2003; 170: 1383-91.
43. Albanesi C, Fairchild H, Madonna S, Scarponi C, De Pità O, Leung D, et al. IL-4 and IL-13 negatively regulate TNF-alpha- and IFN-gamma-induced beta-defensin expression through STAT-6, suppressor of cytokine signaling (SOCS)-1, and SOCS-3. J Immunol 2007; 179: 984-92.
44. Kim S, Izumi Y, Yano M, Hamaguchi A, Miura K, Yamanaka A, et al. Angiotensin blockade inhibits activation of mitogen-activated protein kinases in rat balloon-injured artery. Circulation 1998; 97: 1731-7.
45. Ohashi N, Matsumori A, Furukawa Y, Ono K, Okada M, Iwasaki A, et al. Role of p38 mitogen-activated protein kinase in neointimal hyperplasia after vascular injury. Arterioscler Thromb Vasc Biol 2000; 20: 2521-6.
46. Inoue Y, Otsuka T, Niiro H, Nagano S, Arinobu Y, Ogami E, et al. Novel regulatory mechanisms of CD40-induced prostanoid synthesis by IL-4 and IL-10 in human monocytes. J Immunol 2004; 172: 2147-54.
47. Ward C, Murray J, Clugston A, Dransfield I, Haslett C, Rossi A. Interleukin-10 inhibits lipopolysaccharide-induced survival and extracellular signal-regulated kinase activation in human neutrophils. Eur J Immunol 2005; 35: 2728-37.
48. Nagano S, Otsuka T, Niiro H, Yamaoka K, Arinobu Y, Ogami E, et al. Molecular mechanisms of lipopolysaccharide-induced cyclooxygenase-2 expression in human neutrophils: involvement of the mitogen-activated protein kinase pathway and regulation by anti-inflammatory cytokines. Int Immunol 2002; 14: 733-40.
49. Collins T. Endothelial nuclear factor-kappa B and the initiation of the atherosclerotic lesion. Lab Invest 1993; 68: 499-508.
50. Hanada T, Yoshimura A. Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev 2002; 13: 413-21.
51. Pousset F, Dantzer R, Kelley KW, Parnet P. Interleukin-1 signaling in mouse astrocytes involves Akt: a study with interleukin-4 and IL-10. Eur Cytokine Net 2000; 11: 427-34.
52. Trepicchio W, Dorner A. Interleukin-11. A gp130 cytokine. Ann NY Acad Sci 1998; 856: 12-21.
53. Mazighi M, Pelle A, Gonzalez W, Mtairag el M, Philippe M, Henin D, et al. IL-10 inhibits vascular smooth muscle cell activation in vitro and in vivo. Am J Physiol Heart Circ Physiol 2004; 287: H866-71.
54. Zimmerman M, Selzman C, Reznikov L, Raeburn C, Barsness K, McIntyre R Jr, et al. Interleukin-11 attenuates human vascular smooth muscle cell proliferation. Am J Physiol Heart Circ Physiol 2002; 283: 75-80.
55. Donnelly R, Crofford L, Freeman S, Buras J, Remmers E, Wilder R, et al. Tissue-specific regulation of IL-6 production by IL-4. Differential effects of IL-4 on nuclear factor-kappa B activity in monocytes and fibroblasts. J Immunol 1993; 151: 5603-12.
56. Abu-Amer Y. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. J Clin Invest 2001; 107: 1375-85.
57. Lentsch A, Shanley T, Sarma V, Ward P. In vivo suppression of NF-kappa B and preservation of I kappa B alpha by interleukin-10 and interleukin-13. J Clin Invest 1997; 100: 2443-8.
58. Richard M, Louahed J, Demoulin J, Renauld J. Interleukin-9 regulates NF-kappaB activity through BCL3 gene induction. Blood 1999; 93: 4318-27.
59. Park S, Kim K, Hwang H, Kim T. Regulatory effect of SOCS on NF-kappaB activity in murine monocytes/macrophages. DNA Cell Biol 2003; 22: 131-9.
60. Ryo A, Suizu F, Yoshida Y, Perrem K, Liou Y, Wulf G, et al. Regulation of NF-kappaB signaling by Pin1-dependent prolyl isomerization and ubiquitin-mediated proteolysis of p65/RelA. Mol Cell 2003; 12: 1413-26.
61. Khachigian L, Lindner V, Williams A, Collins T. Egr-1-induced endothelial gene expression: A common theme in vascular injury. Science 1996; 271: 1427-31.
62. Khachigian L, Collins, T. Inducible expression of Egr-1-dependent genes. a paradigm of transcriptional activation in vascular endothelium. Circ Res 1997; 81: 457-61.
63. Thiel G, Cibelli G. Regulation of life and death by the zinc finger transcription factor Egr-1. J Cell Physiol 2002; 193: 287-92.
64. Kamimura M, Viedt C, Dalpke A, Rosenfeld M, Mackman N, Cohen D, et al. Interleukin-10 suppresses tissue factor expression in lipopolysaccharide-stimulated macrophages via inhibition of Egr-1 and a serum response element/MEK-ERK1/2 pathway. Circ Res 2005; 97: 305-13.
65. Katsanou V, Papadaki O, Milatos S, Blackshear P, Anderson P, Kollias G, et al. HuR as a negative posttranscriptional modulator in inflammation. Mol Cell 2005; 19: 777-89.
66. Rajasingh J, Bord E, Luedemann C, Asai J, Hamada H, Thorne T, et al. IL-10-induced TNF-alpha mRNA destabilization is mediated via IL-10 suppression of p38 MAP kinase activation and inhibition of HuR expression. FASEB J 2006; 20: 2112-4.
67. Kloss S, Rodenbach D, Bordel R, Mulsch A. Human-antigen R (HuR) expression in hypertension: downregulation of the mRNA stabilizing protein HuR in genetic hypertension. Hypertension 2005; 45: 1200-6.
68. Lin FY, Chen YH, Lin YW, Tsai JS, Chen JW, Wang HJ, et al. The role of human antigen R, an RNA-binding protein, in mediating the stabilization of toll-like receptor 4 mRNA induced by endotoxin: a novel mechanism involved in vascular inflammation. Arterioscler Thromb Vasc Biol 2006; 26: 2622-9.
69. Pullmann R Jr, Juhaszova M, Lopez de Silanes I, Kawai T, Mazan-Mamczarz K, Halushka M, et al. Enhanced proliferation of cultured human vascular smooth muscle cells linked to increased function of RNA-binding protein HuR. J Biol Chem 2005; 280: 22819-26.
70. Cuneo A, Autieri M. The anti-inflammatory cytokine IL-19 suppresses VSMC activation by attenuation of proliferative and inflammatory gene expression. (Abstract) FASEB J 2008; 22: 900-6.
71. Mallat Z, Heymes C, Ohan J, Faggin E, Lesèche G, Tedgui A. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol 1999; 19: 611-6.
72. Wang CY, Liu PY, Liao JK. Pleotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2007; 14: 37-44.
73. Huang KC, Chen CW, Chen JC, Lin WW. Statins induce suppressor of cytokine signaling-3 in macrophages. FEBS Lett 2003; 555: 385-9.
74. Dunn SE, Youssef S, Goldstein MJ, Prod'homme T, Weber MS, Zamvil SS, et al. Isoprenoids determine Th1/Th2 fate in pathogenic T cells, providing a mechanism of modulation of autoimmunity by atorvastatin. J Exp Med 2006; 203: 401-12.
75. Youssef S, Stüve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune Nature 2002; 420: 78-84.
76. Fichtlscherer S, Breuer S, Heeschen C, Dimmeler S, Zeiher AM. Interleukin-10 serum levels and systemic endothelial vasoreactivity in patients with coronary artery disease. J Am Coll Cardiol 2004; 44: 44-9.
77. Mallat Z, Besnard S, Duriez M, Deleuze V, Emmanuel F, Bureau MF, et al. Protective role of interleukin-10 in atherosclerosis. Circ Res 1999; 85: e17-24.
78. Pinderski Oslund L, Hedrick C, Olvera T, Hagenbaugh A, Territo M, Berliner J, et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999; 19: 2847-53.
79. Caligiuri G, Rudling M, Ollivier V, Jacob M, Michel J, Hansson G, et al. Interleukin-10 deficiency increases atherosclerosis, thrombosis, and low-density lipoproteins in apolipoprotein E knockout mice. Mol Med 2003; 9: 10-7.
80. Mostafa Mtairag E, Chollet-Martin S, Oudghiri M, Laquay N, Jacob M, Michel J, et al. Effects of interleukin-10 on monocyte/endothelial cell adhesion and MMP-9/TIMP-1 secretion. Cardiovasc Res 2001; 49: 882-90.
81. Pinderski L, Fischbein M, Subbanagounder G, Fishbein M, Kubo N, Cheroutre H, et al. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes. Circ Res 2002; 90: 1064-71.
82. Liu Y, Li D, Chen J, Xie J, Bandyopadhyay S, Zhang D, et al. Inhibition of atherogenesis in LDLR knockout mice by systemic delivery of adeno-associated virus type 2-hIL-10. Atherosclerosis 2006; 188: 19-27.
83. Namiki M, Kawashima S, Yamashita T, Ozaki M, Sakoda T, Inoue N, et al. Intramuscular gene transfer of interleukin-10 cDNA reduces atherosclerosis in apolipoprotein E-knockout mice. Atherosclerosis 2004; 172: 21-9.
84. Yoshioka T, Okada T, Maeda Y, Ikeda U, Shimpo M, Nomoto T, et al. Adeno-associated virus vector-mediated interleukin-10 gene transfer inhibits atherosclerosis in apolipoprotein E-deficient mice. Gene Ther 2004; 11: 1772-9.
85. Eefting D, Schepers A, De Vries MR, Pires NM, Grimbergen JM, Lagerweij T, et al. The effect of interleukin-10 knock-out and overexpression on neointima formation in hypercholesterolemic APOE*3-Leiden mice. Atherosclerosis 2007; 193: 335-42.
86. Rubic T, Lorenz RL. Downregulated CD36 and oxLDL uptake and stimulated ABCA1/G1 and cholesterol efflux as anti-atherosclerotic mechanisms of interleukin-10. Cardiovasc Res 2006; 69: 527-35.
87. Rectenwald JE, Minter RM, Moldawer LL, Abouhamze Z, La Face D, Hutchins E, et al. Interleukin-10 fails to modulate low shear stress-induced neointimal hyperplasia. J Surg Res 2002; 102: 110-8.
88. Zimmerman M, Reznikov L, Raeburn C, Selzman C. Interleukin-10 attenuates the response to vascular injury. J Surg Res 2004; 121: 206-13.
89. Feldman L, Aguirre L, Ziol M, Bridou J, Nevo N, Michel J, et al. Interleukin-10 inhibits intimal hyperplasia after angioplasty or stent implantation in hypercholesterolemic rabbits. Circulation 2000; 101: 908-16.
90. Potteaux S, Esposito B, van Oostrom O, Brun V, Ardouin P, Groux H, et al. Leukocyte-derived interleukin 10 is required for protection against atherosclerosis in low-density lipoprotein receptor knockout mice. Arterioscler Thromb Vasc Biol 2004; 24: 1474-8.
91. George J, Mulkins M, Shaish A, Casey S, Schatzman R, Sigal E, et al. Interleukin (IL)-4 deficiency does not influence fatty streak formation in C57BL/6 mice. Atherosclerosis 2000; 153: 403-11.
92. King V, Cassis L, Daugherty A. Interleukin-4 does not influence development of hypercholesterolemia or angiotensin II-induced atherosclerotic lesions in mice. Am J Pathol 2007; 171: 2040-7.
93. Davenport P, Tipping P. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Am J Pathol 2003; 163: 1117-25.
94. Grohmann U, Van Snick J, Campanile F, Silla S, Giampietri A, Vacca C, et al. IL-9 protects mice from Gram-negative bacterial shock: suppression of TNF-alpha, IL-12, and IFN-gamma, and induction of IL-10. J Immunol 2000; 164: 4197-203.
95. Frostegård J, Ulfgren AK, Nyberg P, Hedin U, Swedenborg J, Andersson U, et al. Cytokine expression in advanced human atherosclerotic plaques: dominance of pro-inflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis 1999; 145: 33-43.
96. Vadiveloo P, Stanton H, Cochran F, Hamilton J. Interleukin-4 inhibits human smooth muscle cell proliferation. Artery 1994; 21: 161-81.
97. Vadiveloo P, Filonzi E, Stanton H, Hamilton J. G1 phase arrest of human smooth muscle cells by heparin, IL-4 and cAMP is linked to repression of cyclin D1 and cdk2. Atherosclerosis 1997; 133: 61-9.
98. Barks J, McQuillan J, Iademarco M. TNF-alpha and IL-4 synergistically increase vascular cell adhesion molecule-1 expression in cultured vascular smooth muscle cells. J Immunol 1997; 159: 4532-8.
99. Lee YW, Kühn H, Hennig B, Neish AS, Toborek M. IL-4-induced oxidative stress upregulates VCAM-1 gene expression in human endothelial cells. J Mol Cell Cardiol 2001; 33: 83-94.
100. Walch L, Massade L, Dufilho M, Brunet A, Rendu F. Proatherogenic effect of interleukin-4 in endothelial cells: modulation of oxidative stress, nitric oxide and monocyte chemoattractant protein-1 expression. Atherosclerosis 2006; 187: 285-91.
101. Lee YW, Eum SY, Chen KC, Hennig B, Toborek M. Gene expression profile in interleukin-4-stimulated human vascular endothelial cells. Mol Med 2004; 10: 19-27.
102. Fukushi J, Ono M, Morikawa W, Iwamoto Y, Kuwano M. The activity of soluble VCAM-1 in angiogenesis stimulated by IL-4 and IL-13. J Immunol 2000; 165: 2818-23.
103. Grehan JF, Levay-Young BK, Fogelson JL, François-Bongarçon V, Benson BA, Dalmasso AP. IL-4 and IL-13 induce protection of porcine endothelial cells from killing by human complement and from apoptosis through activation of a phosphatidylinositide 3-kinase/Akt pathway. J Immunol 2005; 175: 1903-10.
104. Jordan NJ, Watson ML, Williams RJ, Roach AG, Yoshimura T, Westwick J. Chemokine production by human vascular smooth muscle cells: modulation by IL-13. Br J Pharmacol 1997; 122: 749-57.
105. Ruetten H, Thiemermann C. Interleukin-13 is a more potent inhibitor of the expression of inducible nitric oxide synthase in smooth muscle cells than in macrophages: a comparison with interleukin-4 and interleukin-10. Shock 1997; 8: 409-14.
106. Chen X, Kelemen S, Autieri M. Expression of granulocyte colony-stimulating factor is induced in injured rat carotid arteries and mediates vascular smooth muscle cell migration. Am J Physiol Cell Physiol 2005; 288: C81-8.
107. Autieri M, Carbone C, Mu A. Expression of allograft inflammatory factor-1 is a marker of activated human vascular smooth muscle cells and arterial injury. Arterioscler Thromb Vasc Biol 2000; 20: 1737-44.
108. Taki H, Sakai T, Sugiyama E, Mino T, Kuroda A, Taki K, et al. Monokine stimulation of interleukin-11 production by human vascular smooth muscle cells in vitro. Atherosclerosis 1999; 144: 375-80.
109. Kirkiles-Smith N, Mahboubi K, Plescia J, McNiff J, Karras J, Schechner J, et al. IL-11 protects human microvascular endothelium from alloinjury in vivo by induction of survivin expression. J Immunol 2004; 172: 1391-6.
110. Temann U, Laouar Y, Eynon E, Homer R, Flavell R. IL9 leads to airway inflammation by inducing IL13 expression in airway epithelial cells. Int Immunol 2007; 19: 1-10.
111. Oral H, Kotenko S, Yilmaz M, Mani O, Zumkehr J, Blaser K, et al. Regulation of T cells and cytokines by the interleukin-10 (IL-10)-family cytokines IL-19, IL-20, IL-22, IL-24 and IL-26. Eur J Immunol 2006; 36: 380-8.